Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2041 to 2055 of 9025 results

  1. Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]

    Awaiting development Reference number: GID-TA11425 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]

    Awaiting development Reference number: GID-TA11404 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Concizumab for treating severe haemophilia A or moderate to severe haemophilia B in people 12 years and over without inhibitors [ID5099]

    Awaiting development Reference number: GID-TA10972 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]

    Awaiting development Reference number: GID-TA10453 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Remibrutinib for treating chronic inducible urticaria inadequately controlled by H1-antihistamines [ID6742]

    Awaiting development Reference number: GID-TA11968 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Gilteritinib with standard chemotherapy for newly diagnosed FLT3-mutation-positive acute myeloid leukaemia when intensive chemotherapy is suitable [TSID12331]

    Awaiting development Reference number: GID-TA11936 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Pharmalgen for the treatment of bee and wasp venom allergy

    In development Reference number: GID-TA11898 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Epcoritamab + R-CHOP for Diffuse large B-cell lymphoma (DLBCL) [TSID12334]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Transarterial radio embolisation for osteosarcoma liver metastases

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  10. Emicizumab for preventing bleeding episodes in people with mild or moderate haemophilia A [ID5098]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Helge for detecting haemolysis

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  12. Setrusumab for treating osteogenesis imperfecta [ID6730]

    Awaiting development Reference number: GID-TA11921 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Medicines for treating osteoporosis and reducing the risk of fragility fractures (review of TA160, TA161, TA204, TA464, TA791, TA991) [ID6689]

    Awaiting development Reference number: GID-TA11907 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Bariatric left gastric artery embolisation

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  15. Fibreoptic endoscopic evaluation of swallowing (FEES)

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation